Css LLC Exact Sciences Corp Transaction History

Css LLC

$999 Million
Q3 2024

A detailed history of Css LLC transactions in Exact Sciences Corp stock. As of the latest transaction made, Css LLC holds 10,600 shares of EXAS stock, worth $522,898. This represents 0.07% of its overall portfolio holdings.

Number of Shares

10,600

Holding current value

$522,898

% of portfolio

0.07%

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$42.43 - $70.83 $449,758 - $750,798	10,600 New	10,600 $721,000
Q2 2021 Aug 16, 2021	SELL	$93.66 - $139.27 $112,953 - $167,959	-1,206 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$116.57 - $155.01 $1.32 Million - $1.76 Million	-11,322 Reduced 90.37%	1,206 $159,000
Q4 2020 Feb 16, 2021	BUY	$99.61 - $142.12 $956,256 - $1.36 Million	9,600 Added 327.87%	12,528 $1.66 Million
Q3 2020 Nov 16, 2020	SELL	$72.92 - $102.01 $58,481 - $81,812	-802 Reduced 21.5%	2,928 $299,000
Q1 2020 May 15, 2020	SELL	$37.9 - $104.44 $1.6 Million - $4.4 Million	-42,137 Reduced 91.87%	3,730 $216,000
Q4 2019 Feb 14, 2020	BUY	$77.66 - $99.74 $2.61 Million - $3.35 Million	33,596 Added 273.78%	45,867 $4.24 Million
Q4 2018 Feb 14, 2019	BUY	$56.04 - $82.66 $687,666 - $1.01 Million	12,271 New	12,271 $774,000

Others Institutions Holding EXAS

# of Institutions

671

Shares Held

163M

Call Options Held

2.58M

Put Options Held

2.19M

Vanguard Group Inc Valley Forge, PA

17.8M
Shares

$876 Million
0.02% of portfolio
Capital World Investors Los Angeles, CA

15.8M
Shares

$781 Million
0.17% of portfolio
Wellington Management Group LLP Boston, MA

14.3M
Shares

$707 Million
0.18% of portfolio
Black Rock Inc. New York, NY

12.1M
Shares

$595 Million
0.01% of portfolio
State Street Corp Boston, MA

6.68M
Shares

$330 Million
0.02% of portfolio

View Full List

About EXACT SCIENCES CORP

Ticker EXAS
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 176,960,000
Market Cap $8.73B
Description
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...

More about EXAS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Css LLC, based on Form 13F filings with the SEC.

News

Stay updated on Css LLC with notifications on news.

Account